BeOne Medicines (ONC) Cash from Financing Activities (2015 - 2026)

BeOne Medicines (ONC) has 12 years of Cash from Financing Activities data on file, last reported at $68.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 303.19% year-over-year to $68.6 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 44428.88% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 447.66% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $68.6 million, down from $96.9 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for ONC reached as high as $961.3 million in Q3 2025 and fell as low as -$110.4 million in Q4 2022.
• Historically, Cash from Financing Activities has averaged $101.1 million across 5 years, with a median of $23.0 million in 2024.
• Across the five-year window, Cash from Financing Activities sank 163.86% in 2023 and soared 7491.79% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$110.4 million in 2022, then surged by 414.45% to $347.0 million in 2023, then tumbled by 101.3% to -$4.5 million in 2024, then soared by 2243.07% to $96.9 million in 2025, then fell by 29.19% to $68.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $68.6 million in Q1 2026, $96.9 million in Q4 2025, and $961.3 million in Q3 2025.